Stay updated on Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial

Sign up to get notified when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    8 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added and Revision: v3.4.3 was removed in the Record History.
    Difference
    0.1%
    Check dated 2026-03-18T17:43:55.000Z thumbnail image
  3. Check
    15 days ago
    Change Detected
    Summary
    The record history now includes a new revision entry v3.4.3 and removes the previous revision v3.4.2.
    Difference
    0.1%
    Check dated 2026-03-11T14:46:33.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    43 days ago
    Change Detected
    Summary
    The study record now shows a Completed status with updated Study Status and Recruitment Status, and new References and Contacts/Locations sections have been added. The previous government-funding operating status notice has been removed.
    Difference
    1.0%
    Check dated 2026-02-11T02:13:29.000Z thumbnail image
  6. Check
    50 days ago
    Change Detected
    Summary
    Added a site-wide funding-status notice and updated the revision to v3.4.1 (replacing v3.4.0).
    Difference
    0.5%
    Check dated 2026-02-03T22:53:40.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The history page now displays a glossary, uses green/red highlights to show additions and deletions, and updates the revision label to v3.4.0 (replacing v3.3.4), with minor textual tweaks like capitalization of 'FEAR Act Data'.
    Difference
    0.6%
    Check dated 2026-01-27T20:59:22.000Z thumbnail image
  8. Check
    93 days ago
    Change Detected
    Summary
    Footer metadata updated with Revision: v3.3.3 and removal of HHS Vulnerability Disclosure and Revision: v3.3.2.
    Difference
    0.1%
    Check dated 2025-12-23T00:33:40.000Z thumbnail image

Stay in the know with updates to Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.